PE20090875A1 - Derivados de tetrazol como moduladores de los receptores de glutamato metabotropicos - Google Patents
Derivados de tetrazol como moduladores de los receptores de glutamato metabotropicosInfo
- Publication number
- PE20090875A1 PE20090875A1 PE2008001783A PE2008001783A PE20090875A1 PE 20090875 A1 PE20090875 A1 PE 20090875A1 PE 2008001783 A PE2008001783 A PE 2008001783A PE 2008001783 A PE2008001783 A PE 2008001783A PE 20090875 A1 PE20090875 A1 PE 20090875A1
- Authority
- PE
- Peru
- Prior art keywords
- modulators
- methyl
- metabotropic glutamate
- glutamate receptors
- tetrazol
- Prior art date
Links
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 title abstract 3
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 title abstract 3
- 150000003536 tetrazoles Chemical class 0.000 title abstract 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 3-METHYLPHENYL Chemical class 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010044688 Trisomy 21 Diseases 0.000 abstract 1
- 201000006549 dyspepsia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- 238000010992 reflux Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98129407P | 2007-10-19 | 2007-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090875A1 true PE20090875A1 (es) | 2009-08-08 |
Family
ID=40567640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008001783A PE20090875A1 (es) | 2007-10-19 | 2008-10-17 | Derivados de tetrazol como moduladores de los receptores de glutamato metabotropicos |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7960422B2 (enExample) |
| EP (1) | EP2231647A4 (enExample) |
| JP (1) | JP2011500673A (enExample) |
| KR (1) | KR20100090777A (enExample) |
| CN (1) | CN101896480A (enExample) |
| AR (1) | AR068921A1 (enExample) |
| AU (1) | AU2008312055A1 (enExample) |
| BR (1) | BRPI0818448A2 (enExample) |
| CA (1) | CA2703425A1 (enExample) |
| CL (1) | CL2008003085A1 (enExample) |
| CO (1) | CO6321281A2 (enExample) |
| CR (1) | CR11376A (enExample) |
| DO (1) | DOP2010000119A (enExample) |
| EA (1) | EA201000654A1 (enExample) |
| IL (1) | IL204958A0 (enExample) |
| MX (1) | MX2010004272A (enExample) |
| PE (1) | PE20090875A1 (enExample) |
| TW (1) | TW200934771A (enExample) |
| UY (1) | UY31403A1 (enExample) |
| WO (1) | WO2009051556A1 (enExample) |
| ZA (1) | ZA201002694B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1847543A1 (de) | 2006-04-19 | 2007-10-24 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen |
| DK2610258T3 (da) * | 2007-10-19 | 2014-11-10 | Boehringer Ingelheim Int | Substituerede piperidindihydrothienopyrimidiner |
| JP5563466B2 (ja) | 2007-10-19 | 2014-07-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ピペラジノ−ジヒドロチエノピリミジン誘導体 |
| CN101827853A (zh) | 2007-10-19 | 2010-09-08 | 贝林格尔.英格海姆国际有限公司 | 杂环取代的哌嗪子基-二氢噻吩并嘧啶 |
| MX2011003011A (es) | 2008-09-22 | 2011-09-01 | Cayman Chem Co | Compuestos de multiheteroarilo como inhibidores de prostaglandina d sintasa hematopoyetica y su uso para tratar enfermedades mediadas por prostaglandina d2. |
| EP2379531A1 (en) * | 2008-12-18 | 2011-10-26 | AstraZeneca AB | Processes for the manufacture of 3-{4-methyl-5- [ (ir) -1- (2- (3-methylphenyl) -2h-tetrazol-5-yl) -ethoxy]-4h- [1,2, 4]triazol-3-yl} -pyridine, 4-methyl-3-methylthio-5- (3- pyridyl)-l,2,4-triazole, and (ir) -1- [2- (3-methylphenyl) -2h- tetrazol-5-yl]ethanol |
| AU2010255552A1 (en) | 2009-06-05 | 2012-01-12 | Oslo University Hospital Hf | Azole derivatives as Wtn pathway inhibitors |
| EP2649063A1 (en) | 2010-12-08 | 2013-10-16 | Oslo University Hospital HF | Triazole derivatives as wnt signaling pathway inhibitors |
| EP2685977A1 (en) | 2011-03-18 | 2014-01-22 | Novartis AG | COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE |
| US20130059866A1 (en) | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
| US9802954B2 (en) | 2011-08-24 | 2017-10-31 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
| CN106032377A (zh) * | 2015-03-12 | 2016-10-19 | 天津药物研究院有限公司 | 四氮唑类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663332A (en) | 1985-10-10 | 1987-05-05 | Hoffman-La Roche Inc. | 5-substituted N-alkylated tetrazoles |
| US5492919A (en) | 1991-08-03 | 1996-02-20 | Smithkline Beecham P.L.C. | 5-HT4 receptor antagonists |
| DE10023430A1 (de) | 2000-05-12 | 2001-11-15 | Bayer Ag | Substituierte N-Benzoyl-N'-(tetrazolylphenyl)-harnstoffe |
| GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| ATE396186T1 (de) | 2001-10-04 | 2008-06-15 | Merck & Co Inc | Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5 |
| US7592337B2 (en) | 2002-03-12 | 2009-09-22 | Merck & Co., Inc. | Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| CN1894241A (zh) * | 2002-08-09 | 2007-01-10 | 阿斯利康(瑞典)有限公司 | 作为代谢型谷氨酸受体－5调节剂的“1,2,4” 噁二唑 |
| WO2005077345A1 (en) * | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
| BRPI0507501A (pt) * | 2004-02-18 | 2007-06-26 | Astrazeneca Ab | composto, composição farmacêutica, uso do composto, método para o tratamento de distúrbios mediados por mglur5, e, método para inibir a ativação de receptores de mglur5 |
| US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| SG149900A1 (en) | 2004-02-18 | 2009-02-27 | Astrazeneca Ab | Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists |
| AU2005214379B2 (en) * | 2004-02-18 | 2012-03-22 | Astrazeneca Ab | Tetrazole compounds and their use as metabotropic glutamate receptor antagonits |
| UY29796A1 (es) | 2005-09-29 | 2007-04-30 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor |
| TW200811156A (en) | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators IV |
| TW200811157A (en) | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators I |
-
2008
- 2008-10-17 TW TW097139967A patent/TW200934771A/zh unknown
- 2008-10-17 MX MX2010004272A patent/MX2010004272A/es not_active Application Discontinuation
- 2008-10-17 AR ARP080104548A patent/AR068921A1/es unknown
- 2008-10-17 CN CN2008801179810A patent/CN101896480A/zh active Pending
- 2008-10-17 CA CA2703425A patent/CA2703425A1/en not_active Abandoned
- 2008-10-17 JP JP2010529900A patent/JP2011500673A/ja active Pending
- 2008-10-17 AU AU2008312055A patent/AU2008312055A1/en not_active Abandoned
- 2008-10-17 EA EA201000654A patent/EA201000654A1/ru unknown
- 2008-10-17 BR BRPI0818448 patent/BRPI0818448A2/pt not_active IP Right Cessation
- 2008-10-17 CL CL2008003085A patent/CL2008003085A1/es unknown
- 2008-10-17 EP EP08840285A patent/EP2231647A4/en not_active Withdrawn
- 2008-10-17 KR KR1020107010834A patent/KR20100090777A/ko not_active Withdrawn
- 2008-10-17 PE PE2008001783A patent/PE20090875A1/es not_active Application Discontinuation
- 2008-10-17 UY UY31403A patent/UY31403A1/es unknown
- 2008-10-17 WO PCT/SE2008/051170 patent/WO2009051556A1/en not_active Ceased
- 2008-10-17 US US12/285,988 patent/US7960422B2/en not_active Expired - Fee Related
-
2010
- 2010-04-08 IL IL204958A patent/IL204958A0/en unknown
- 2010-04-16 ZA ZA2010/02694A patent/ZA201002694B/en unknown
- 2010-04-19 CR CR11376A patent/CR11376A/es not_active Application Discontinuation
- 2010-04-19 DO DO2010000119A patent/DOP2010000119A/es unknown
- 2010-04-28 CO CO10050285A patent/CO6321281A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2703425A1 (en) | 2009-04-23 |
| KR20100090777A (ko) | 2010-08-17 |
| ZA201002694B (en) | 2011-03-30 |
| BRPI0818448A2 (pt) | 2015-05-12 |
| DOP2010000119A (es) | 2010-05-31 |
| JP2011500673A (ja) | 2011-01-06 |
| CL2008003085A1 (es) | 2009-10-09 |
| US20090131454A1 (en) | 2009-05-21 |
| IL204958A0 (en) | 2010-11-30 |
| AU2008312055A1 (en) | 2009-04-23 |
| AR068921A1 (es) | 2009-12-16 |
| EP2231647A4 (en) | 2011-08-31 |
| EP2231647A1 (en) | 2010-09-29 |
| CR11376A (es) | 2010-07-19 |
| US7960422B2 (en) | 2011-06-14 |
| UY31403A1 (es) | 2009-05-29 |
| CO6321281A2 (es) | 2011-09-20 |
| MX2010004272A (es) | 2010-04-30 |
| WO2009051556A1 (en) | 2009-04-23 |
| CN101896480A (zh) | 2010-11-24 |
| TW200934771A (en) | 2009-08-16 |
| EA201000654A1 (ru) | 2010-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090875A1 (es) | Derivados de tetrazol como moduladores de los receptores de glutamato metabotropicos | |
| PE20080951A1 (es) | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS | |
| PE20090328A1 (es) | Derivados de oxadiazol como moduladores de los receptores metabotropicos de glutamato | |
| PE20091042A1 (es) | Ligandos de oxadiazol del receptor metabotropico del glutamato y su uso como potenciadores - 841 | |
| PE20110136A1 (es) | Compuestos organicos | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| PE20051173A1 (es) | Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3 | |
| PE20081884A1 (es) | Inhibidores heterociclicos de la aspartil proteasa | |
| PE20081532A1 (es) | Compuestos novedosos | |
| PE20141529A1 (es) | Derivados de biciclo [3,2,1] octilamida y sus usos | |
| TW200637550A (en) | Thiazole-4-carboxamide derivatives as mGluR5 antagonists | |
| PE20090312A1 (es) | DERIVADO DE 17 -CIANO-18a-HOMO-19-NOR-ANDROST-4-ENO | |
| PE20091035A1 (es) | Derivados de 2-aminopirimidina | |
| EA200970326A1 (ru) | Алкильные производные в качестве метаботропных рецепторов глутамата | |
| PE20110341A1 (es) | COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA | |
| JP2009533410A5 (enExample) | ||
| PE20090816A1 (es) | Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 | |
| PE20081659A1 (es) | Agonistas de gpcr | |
| PE20080858A1 (es) | Compuestos de n-aril pirazol y composiciones que los contienen | |
| PE20130227A1 (es) | Formulaciones farmaceuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt | |
| PE20110433A1 (es) | Antagonistas de la via hedgehog de ftalazina disustituida | |
| PE20140934A1 (es) | Derivados de pirazol | |
| PE20091057A1 (es) | Antagonistas del receptor mineralcorticoide y metodos de uso | |
| PE20060079A1 (es) | DERIVADOS DE PIRIDILO COMO ANTAGONISTAS DEL RECEPTOR mGlus5 | |
| PE20060937A1 (es) | Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |